For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$99.97
Thesis
Lantheus is a commercial-stage leader in radiopharmaceutical diagnostics with a market-leading prostate cancer PET imaging agent. Cash flow from established products funds expansion into therapeutic radioligands.
Catalysts
- Pylarify volume growth and competitive defense
- Therapeutic radioligand pipeline build-out
- Business development in diagnostics and therapy
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Sep 8M&ASEC
Filed DEFM14A definitive proxy statement for merger or acquisition.
- Aug 26M&ASEC
PREM14A preliminary proxy statement filed for merger or acquisition.
- Aug 6Financial resultsSEC
Lantheus Holdings files 8-K (items 2.02, 9.01) disclosing results of operations and financial condition.
- Aug 4LeadershipSEC
8-K reports entry into material definitive agreement (item 1.01) and officer/director changes (item 5.02).
- Aug 3OtherSEC
Lantheus Holdings files 8-K covering items 7.01 (Reg FD), 8.01 (other events), and 9.01 (exhibits).
- Jul 22RegulatoryFDA
FDA supplemental submission (SUPPL-41) action for NEURACEQ under NDA204677.